Physician profile
Nir N Somekh
NPI 1053579953
$10,192.54
in general payments reported to CMS, 2019-2025
35 companies · $1,424 in 2025
The $1,424 reported for 2025 was more than what 78% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,246 · 2020: $1,074 · 2021: $1,627 · 2022: $1,441 · 2023: $1,403 · 2024: $1,978 · 2025: $1,424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,805.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,805.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,154.74 | 2019-2025 | Farxiga |
| Janssen Pharmaceuticals, INC | $1,053.32 | 2019-2024 | Xarelto |
| Amgen INC. | $1,007.98 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $993.77 | 2019-2025 | |
| Abbott Laboratories | $719.61 | 2019-2024 | Aveir |
| E.R. Squibb & Sons, L.L.C. | $669.30 | 2019-2025 | Eliquis, Camzyos |
| Pfizer INC. | $623.33 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $545.12 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $529.63 | 2021-2025 | Verquvo |
| Sanofi-Aventis U.S. LLC | $288.04 | 2019-2023 | |
| Boston Scientific Corporation | $252.41 | 2019-2025 | Watchman Flx, Watchman Access System |
| Bayer Healthcare Pharmaceuticals INC. | $244.98 | 2025 | |
| Cvrx, INC. | $241.23 | 2024-2025 | Barostim Neo System |
| Medtronic, INC. | $229.48 | 2023-2024 | Selectsecure, Cobalt Dr Mri Surescan, Micra |
| Amarin Pharma, INC. | $188.07 | 2019-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medicomp INC | $184.86 | 2022-2025 | Telepatch Cardiac Monitor |
| Esperion Therapeutics, INC. | $180.48 | 2020-2025 | Nexletol |
| Impulse Dynamics (USA) INC. | $161.85 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $131.38 | 2023-2024 | Inpefa |
| Medtronic Vascular, INC. | $129.41 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $82.57 | 2019 | |
| Althera Pharmaceuticals LLC | $71.06 | 2021-2022 | |
| Inspire Medical Systems, INC. | $69.12 | 2025 | Inspire |
| Kowa Pharmaceuticals America, INC. | $68.79 | 2019-2020 | |
| Novo Nordisk INC | $62.79 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Heartflow, INC. | $59.90 | 2022-2024 | |
| Lilly USA, LLC | $42.40 | 2019-2025 | Mounjaro, Zepbound |
| Philips North America LLC | $41.28 | 2023 | |
| Bardy Diagnostics, INC. | $33.00 | 2020-2021 | |
| Kestra Medical Technology Services, INC. | $27.97 | 2022 | |
| Irhythm Technologies, INC. | $26.31 | 2021 | |
| Celgene Corporation | $24.71 | 2019 | |
| Scpharmaceuticals INC. | $22.71 | 2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $16.44 | 2025 | Lifevest |
| Ionis Pharmaceuticals, INC. | $14.50 | 2025 | Tryngolza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nir Somekh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.